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age was 72.8 o 8.9 yrs, 65.1% were male and 78.7% had a history of hypertension. 
LTB was calculated as the proportion of patients receiving antihypertensive therapy 
who were not attaining guideline BP control targets. A hypothetical intervention to 
lower blood pressure to the normal range was applied to those individuals identiﬁed 
with LTB, to estimate the number of cardiovascular disease events which could 
be prevented. Logistic regression was used to ﬁnd the predictors of LTB and 
event rates were compared using Chi squared tests. RESULTS: Among the 2856 
Australian REACH participants, 70.1% (n  2002) had uncontrolled blood 
pressure (130/80 mmHg) and 88.3% (2522) had been taking anti-hypertensive 
medication. LTB was 70.7% (1784). The major univariate predictors of LTB 
were gender, age, diabetes, hypertension, carotid plaque, cholesterol, BMI and 
congestive heart failure. Assuming a hypothetical blood pressure intervention is applied 
to the LTB group resulting in controlled blood pressure (a130/80 mmHg), 8 cardiac 
events per 1000 people and 21 cardiovascular disease events including coronary 
heart disease intervention per 1000 people could be prevented. CONCLUSIONS: 
Improving BP control in patients receiving antihypertensive medication may prevent 
8 cardiac events per 1000 people and 21 CVD events per 1000 people within this 
study group. At a population level, this would represent a major cardiovascular event 
reduction strategy.
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OBJECTIVES: Inpatient surgery is a major component of overall health care 
spending. We examined variation in outlier payment across US hospitals and the 
extent to which variation is explained by quality of care. METHODS: We used the 
2006 Medicare Provider Analysis and Review (MEDPAR) ﬁle. We identiﬁed coronary 
artery bypass grafting (CABG).We ﬁrst describe the incidence of outlier payments for 
CABG, average outlier payment amount and their contribution to overall inpatient 
payments. We then explore how outlier payments vary according to patient charac-
teristics and across hospitals. Multiple logistic regression is used to examine to extent 
to which different factors serve as independent predictors of outlier payments. Stan-
dard errors are adjusted for the effect of clustering of outlier payments within hospi-
tals. In assessing variation in outlier payments across hospitals, we described the 
distribution of outlier payment prevalence (proportion of patients associated 
with outlier payments) by hospital. We, then assessed hospital variation using ﬁxed-
efects logistic regression models. RESULTS: The proportion of patients associated 
with outlier payment was 11%. Average outlier payments were considerable: $26,064. 
Outlier payment for CABG cost CMS approximately $480 million in 2006. Outlier 
payments were major contributors to the overall inpatient cost: 12.9%. Approxi-
mately 20% of hospitals had outlier rates below 5% for coronary artery bypass 
surgery, while 25% had outlier rates exceed 20%. Although, there were patient level 
risk factors that determine patient level otulier payment rates, this did not explain 
hospital level variation. Higher volume hospitals were less likely to have patients with 
outlier payments. CONCLUSIONS: Aiming to accelerate the quality improvements, 
payers are increasingly applying value-based purchasing strategies to surgical care. 
We showed that the variation in outlier payments across US hospitals is substantial 
for CABG and patient level risk factors can not explain hospital level variation. 
Hospital and surgical volume as a quality indicator is negatively related with 
outlier payments.
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OBJECTIVES: To assess the cost of percutaneous pulmonary valve implantation 
(PPVI), a new procedure introduced in 2000 as a less invasive treatment for right             
ventricular outﬂow tract (RVOT) dysfunction, and the cost of surgical valve replace-      
ment in patients with right ventricular outﬂow tract dysfunction using a cohort simula-
tion model. METHODS: A cost analysis was performed from the perspective of the 
purchaser (the UK NHS). The cost of PPVI was estimated using data based on a total 
of 141 patients who had undergone PPVI from 2000 to 2008. The cost of surgical 
valve replacement in a similar group of patients was estimated using a cohort simula-
tion model populated with data drawn from the literature and expert opinion, given 
that PPVI has supplanted this procedure in the clinical setting analysed. The model is   
a cohort simulation model and assesses the cost of surgery using a hypothetical popula-
tion of 1000 individuals with right ventricular outﬂow tract dysfunction starting when        
their ﬁrst valved biological conduit was surgically placed and following them for a 
period of 25 years assuming that 1) PPVI is not available as an option, and 2) that 
PPVI is available for those eligible for it. RESULTS: The model resulted in an estimate 
of mean cost per patient of £5276 in the absence of PPVI and in an estimate of mean 
cost per patient of £7958 in the presence of PPVI over the 25 years period of analysis. 
CONCLUSIONS: PPVI although more costly than the surgical alternative, it appears 
to delay surgery thus having a signiﬁcant impact on the health and the quality of life 
of this patient population. More research is needed to quantify the magnitude of the 
impact on the quality of life and to assess the role of modelling generally in assessing 
costs and effects in medical devices.
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OBJECTIVES: The effect of hypertension on increased risk of cardiovascular disease 
events has been demonstrated through population based studies, and the predictive 
value of SBP has been repeatedly demonstrated in risk prediction models derived from 
such studies. A recent meta-analysis of evidence regarding SBP reduction by ARB 
antihypertensives has demonstrated a signiﬁcant difference in the SBP reduction 
observed in patients treated with valsartan, compared to those treated with losartan. 
An economic model has been constructed to evaluate the effect of this difference on 
the risk of a ﬁrst CVD event, and the resulting costs. METHODS: Inputs for the model 
are drawn from published sources and publically available datasets. CVD risk predic-
tion was performed using equations derived from the Framingham Offspring Study 
cohort. The model evaluated an untreated group, and groups treated with valsartan, 
and losartan. Each treatment group was stratiﬁed into those with mild hypertension 
or moderate hypertension. RESULTS: Basecase analyses represent outcomes over 20 
years from baseline moderate HTN classiﬁcation in a US population of age 18 and 
over. Valsartan was associated with a marginal cost of $1,983 vs. the untreated arm, 
and a marginal cost of $466 in comparison to losartan. These costs resulted in esti-
mates of $33,540 per event avoided vs. untreated and $37,484 vs. losartan. Incre-
mental costs per QALY were $7,067 vs. no treatment and $8,067 vs. losartan. 
CONCLUSIONS: Analysis results indicate that reduction in SBP from baseline is 
associated with small reductions in primary CVD rates, and overall CVD treatment 
costs. Valsartan performed better than losartan because it was associated with a 
greater decrease in SBP from baseline (according to meta-analysis results). Overall, the 
calculated cost effectiveness ratios for treatment with valsartan indicate that valsartan 
is likely to be cost-effective when compared to no treatment or treatment with losartan 
in control of SBP.
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OBJECTIVES: To investigate the efﬁciency of minimally-invasive Transcatheter Aortic 
Valve Implantation (TAVI) delivered through the transfemoral or transapical approach 
compared with open-heart conventional aortic valve replacement or medical manage-
ment alone in high risk patients with aortic stenosis in France. METHODS: A longi-
tudinal cohort model was developed to predict clinical and economic outcomes over 
three years in four cohorts of patients treated by either: transfemoral (TF) or transapi-
cal (TA) aortic valve implantation, surgical aortic valve replacement (AVR) or medical 
management (MED). Clinical outcomes included early perioperative complications (30 
days) and late events (stroke, MI, endocarditis, valve reoperation, pacemaker implan-
tation, hospitalization for acute heart failure, and death). In the absence of head-to-
head clinical trials, efﬁcacy data for the alternative approaches were extracted from 
various sources including clinical studies, registries, national health statistics and 
expert opinion. QALYs were assessed by mapping health utilities to NYHA class dis-
tribution. Direct medical costs were assessed by multiplying the number of resource 
items consumed with French unit costs (2008 values). RESULTS: In terms of predicted 
mean life years and QALYs per patient after 3 years, TAVI appears to be superior to 
the other approaches; 2.42 years or 1.76 QALYs for TF, 2.16 years or 1.61 QALYs 
for TA, versus 2.06 years or 1.50 QALYs for AVR, and 1.73 years or 0.98 QALYs 
for MED. Modeled average discounted (3%) cumulative direct medical costs per 
patient amount to a46,677 (TF), a45,468 (TA), a50,630 (AVR), and a78,208 (MED). 
These ﬁndings imply that both transcatheter approaches appear to be dominant versus 
conventional high-risk AVR as well as medical management. Probabilistic sensitivity 
analyses conﬁrmed the robustness of these model results. CONCLUSIONS: TAVI 
appears to be an economically promising technology. However, additional data from 
on-going clinical studies and registries need to be awaited to conﬁrm these preliminary 
results.
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OBJECTIVES: In patients with acute coronary syndromes (ACS) and planned PCI, 
the TRITON-TIMI 38 trial demonstrated that treatment with prasugrel compared 
with clopidogrel was associated with a reduced rate of cardiovascular death/MI/stroke 
and an increased risk of major bleeding. We evaluated the cost-effectiveness of treat-
ment with prasugrel vs. clopidogrel for the duration of the trial, from the perspective 
of the German health care system, based on data from TRITON-TIMI 38. METHODS: 
